Physician

Muath Dawod, M.D.

According to 2025 Medicare claims, Muath Dawod, M.D. (NPI: 1811188253) practices hematology/oncology in the Pueblo, CO market, with the plurality of this provider's patient population coming from Pueblo, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 81003-9998. Dawod is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Dawod's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 481 traditional Medicare patients, billed 118,858 HCPCS/CPT codes, and received $2,297,241 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,355 prescription claims across 216 beneficiaries totaling $5,170,246 in drug costs, led by Revlimid (Lenalidomide). DME data shows 38 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,035,401 to $2,297,241. Similarly, Part D prescription costs have risen steadily, from $917,528 to $5,170,246. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	668	82,989	$1,035,401
2016	772	99,684	$1,455,994
2017	810	111,559	$1,635,119
2018	733	135,191	$2,316,069
2019	624	154,726	$2,099,946
2020	555	138,924	$1,921,665
2021	521	144,342	$2,194,893
2022	484	129,923	$1,711,569
2023	512	156,579	$2,122,955
2024	481	118,858	$2,297,241

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	169	888	$917,528
2016	189	1,096	$1,792,676
2017	184	1,011	$1,973,578
2018	180	1,131	$2,686,353
2019	178	1,065	$2,278,887
2020	180	1,076	$2,968,647
2021	183	1,048	$2,520,747
2022	188	992	$2,513,760
2023	203	1,113	$3,208,912
2024	216	1,355	$5,170,246

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	134	$36,262
2016	N/R	33	$16,941
2017	N/R	41	$8,732
2018	N/R	52	$6,818
2019	N/R	28	$3,418
2020	N/R	11	$1,509
2021	N/R	56	$4,146
2022	N/R	49	$1,711
2023	N/R	33	$15,062
2024	N/R	38	$1,057

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	138	416	$96
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	187	432	$12
80053	Blood test, comprehensive group of blood chemicals	126	482	$10
36415	Insertion of needle into vein for collection of blood sample	211	741	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	199	738	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	48	1,316	$934,866
Pomalyst	Pomalidomide	34	889	$746,717
Ibrance	Palbociclib	47	1,281	$728,350
Lenalidomide	Lenalidomide	23	644	$389,904
Tasigna	Nilotinib Hcl	13	364	$243,346

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$643
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	22	$414

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Muath Dawod, M.D.?

Tedicare shows public-source Medicare data for Muath Dawod, M.D. (NPI 1811188253), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muath Dawod, M.D. have ACO affiliation data?

Muath Dawod, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Muath Dawod, M.D.?

Muath Dawod, M.D. is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Muath Dawod, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.